Fanny Jaulin

Fanny Jaulin, PhD, has a diverse and extensive work experience in the field of oncology. Fanny currently serves as the CEO of Orakl Oncology, where they lead the company's efforts in leveraging tumor avatars and high-quality data to transform oncology drug development. Prior to their current role, Fanny was a research director and principal investigator at Gustave Roussy, where they conducted significant research in the field. Fanny has also held positions as an INSERM Research Group Leader and an ATIP-AVENIR Research Group Leader at INSERM and CNRS respectively. Fanny's career started as a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, where they worked from 2009 to 2012. Prior to that, they were a postdoctoral associate at Weill Cornell Medical College, where they worked from 2004 to 2009.

Fanny Jaulin, PhD, completed their Doctor of Philosophy (Ph.D.) in Molecular network controlling epithelial cell polarity from Aix-Marseille University from 1999 to 2004. Prior to that, they obtained a Master's degree in Cellular and Molecular Biology from Université Paris Cité. In 2022-2023, they pursued further education in business by attending HEC Paris and completing the Challenge + program.